Trial Profile
No-profit clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabetes; randomized, open label, parallel group, controlled clinical study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Rheumatoid arthritis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TRACK
- 03 Mar 2021 Results of long-term follow-up assessing persisted improvement of HbA1c percentage and RA disease activity published in the Clinical and Experimental Rheumatology
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 12 Dec 2018 Status changed from recruiting to discontinued.